NTLA Stock Tumbles 9% as Intellia Bets $180 Million on Its CRISPR Future

The way Intellia Therapeutics has been appearing on traders’ screens lately has an almost theatrical quality. NTLA opened at $12.14 on a muggy Wednesday in late April, briefly rose, and then fell throughout the morning as almost 17 million shares—nearly four times its average daily volume—were traded. The stock had dropped nearly nine percent by New York lunchtime. The pattern would have been evident to anyone watching the tape: a swift bid, followed by sellers intervening, and then another wave. It appeared to be more of a slow dispute between two parties who couldn’t agree on the value of this company than a panic.

As far as anyone can tell, the company’s decision to increase the price of its common stock offering from $150 million to $180 million was the catalyst. The fact that Citi, Goldman Sachs, and Jefferies are in charge of the books gives the transaction some weight. However, the math is harsh. Like the majority of clinical-stage biotechs, Intellia lacks the luxury of profitability to lessen the impact of each new share, which dilutes existing holders. Traders believe that the company timed this increase out of necessity rather than confidence.

The difference between what’s taking place in the lab and on the trading floor is difficult to ignore. The FDA had just lifted a hold on a clinical trial, and Intellia had just two days prior released positive Phase III data for its treatment for hereditary angioedema. These are significant victories. Such news could have caused the stock to rise twenty percent in a different market and mood. Rather, the shares have drifted from the mid-sixteens into the low twelves, burdened by an older shadow: the patient death that was revealed during a crucial study in November 2025, which shattered much of the optimism that had grown around the company.

Naturally, Cathie Wood has a different perspective. On April 27, ARK Invest purchased approximately 263,848 NTLA shares, distributing the purchase between the ARKK and ARKG funds. That amounts to roughly $3.6 million, and it adheres to her well-known strategy of exploiting weakness. Wood has made mistakes in the past, sometimes quite spectacularly. However, she has also been correct on a few points that the consensus completely overlooked. Observing her load up while Goldman Sachs only increases its price target to nine dollars, which is still a Sell rating, highlights a crucial aspect of NTLA at the moment: it’s a stock that investors either firmly believe in or don’t believe in at all.

The argument is not resolved by the fundamentals. Intellia’s quarterly revenue was approximately $23 million, while its operating expenses were close to $122 million. Despite having $449 million on the balance sheet before the raise, the cash burn is high. The company’s CRISPR-based pipeline, which edits genes inside the human body rather than just in petri dishes, is truly unique. Q4 revenue increased by almost 79% year over year. Nevertheless, the consensus among analysts reads like a parliament unable to agree. $58 is seen by Canaccord Genuity. $9 is seen by Goldman. Morgan Stanley is currently worth $15. 25 ratings, no shared reality, citizens at $30.

Perhaps that’s the idea. The NTLA is no longer trading on its quarterly figures. It’s a bet on whether gene editing will be the next big thing in medicine or just a costly side note. Ten years ago, Tesla encountered a similar situation when no one could determine whether Musk was a salesman or a visionary. Nevertheless, the factories continued to operate. There is currently no answer to the question of whether Intellia’s labs perform similarly long enough to be significant. For the time being, the believers continue to buy the dip, the shorts continue to circle, and the chart continues to wobble.